Human papillomavirus (HPV)-related diseases, including cancers, low-grade neoplasia, genital warts, and recurrent respiratory papillomatosis, have a substantial impact on public health. The increasing incidence of HPV infection and genital warts highlights the need for an effective strategy for the management of this disease. Immunization holds the promise of reducing the overall burden of clinical HPV-related diseases. A prophylactic quadrivalent HPV 6/11/16/18 vaccine is highly effective for reducing the risk of HPV 6-, 11-, 16-, and 18-associated cervical cancer, precancerous cervical lesions, and external genital lesions, including genital warts.